MarginsXMarginsX
Home › Markets › Health Care › ANTX

AN2 Therapeutics Inc. (ANTX)

ANTX trades on Nasdaq in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.

Price · November 16, 2026
$4.47
-1.76% on the day
Market cap
$169.6M
Micro cap
Revenue
Not reported in SEC XBRL data
Net income
Not reported in SEC XBRL data

Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026.

Profile

FieldValue
TickerANTX on Nasdaq
SectorHealth Care
IndustryBiotechnology: Pharmaceutical Preparations
CountryUnited States
IPO year2022
SEC CIK0001880438
SEC industry codePharmaceutical Preparations
Incorporated inDE

Financials

Not reported in SEC XBRL data.

Warning signs

Cash runway
8.0 months
$20.2M cash at September 30, 2026
Share count, 1 year
+38.5%
2025-11-03 to 2026-11-05 · +27.6% over 3 years
Going-concern doubt
No
10-Q filed November 9, 2026
Insider net buying, 12 months
-$383K
Through September 30, 2026
SignFindingSource
Going concernNo going-concern finding.10-Q 2026-11-09
Cash and burn$20.2M cash; operating cash flow -$7.6M a quarter.Report 2026-09-30
Shares outstanding37,943,650 (2026-11-05); 27,402,024 a year earlier; 29,741,445 three years earlier.Cover page 2026-11-05
Reverse splits, 3 yearsNone foundNone on EDGAR
Shelf and offerings, 12 months1 S-3/F-3 shelf filings; 1 424B5 takedowns, 1 at the marketLatest 2026-04-20
Exchange deficiency notices, 12 monthsNoneNone on EDGAR
AuditorPricewaterhouseCoopers LLP, San Jose, California, United StatesPCAOB Form AP 2026-03-26
Late filings, 12 monthsNoneNone on EDGAR
Insider trades, 12 monthsBought $12K, sold $395K on the open marketSEC Forms 3/4/5 data sets 2026-09-30

From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.

Quarterly results

QuarterRevenueNet incomeOp. cash flowCashTotal debtTTM revenueSource
Q3 2026
2026-09-30
Not filed-$8.0M-$6.1M$20.2MNo debt tagsNeeds four quarters10-Q 2026-11-09
Q2 2026
2026-06-30
Not filed-$8.2M-$7.0M$44.3MNo debt tagsNeeds four quarters10-Q 2026-11-09
Q1 2026
2026-03-31
Not filed-$10.0M-$12.1M$53.5MNo debt tagsNeeds four quarters10-Q 2026-11-09
Q4 2025
2025-12-31
Not filed-$8.7M-$5.2M$19.9MNo debt tagsNeeds four quarters10-K 2026-03-17
Q3 2025
2025-09-30
Not filed-$9.4M-$6.4M$18.0MNo debt tagsNeeds four quarters10-Q 2026-11-09
Q2 2025
2025-06-30
Not filed-$6.5M-$7.6M$18.2MNo debt tagsNeeds four quarters10-Q 2026-11-09
Q1 2025
2025-03-31
Not filed-$10.6M-$10.6M$20.0MNo debt tagsNeeds four quarters10-Q 2026-11-09
Q4 2024
2024-12-31
Not filed-$7.5M-$5.3M$21.4MNo debt tagsNeeds four quarters10-K 2026-03-17

From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).

Key SEC documents

DocumentFormFiled
Latest prospectus or offering document424B32026-04-20
Latest annual report10-K2026-03-17
Latest quarterly / interim10-Q2026-11-09
Latest current report8-K2026-11-09
Latest proxyDEFA14A2026-04-22

Source: SEC EDGAR submissions feed, 390 recent filings. All filings on EDGAR.

Price moves

WindowReturn
1 week+13.7%
1 month+26.4%
3 months-23.9%
Year to date+299.1%
1 year+302.7%
From 52-week high-27.5%

Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.

Peers in Biotechnology: Pharmaceutical Preparations

TickerCompanyPriceDayMarket cap
ORMPOramed Pharmaceuticals Inc.$3.90+5.12%$169.6M
PYXSPyxis Oncology Inc.$1.41-10.76%$168.6M
PRQRProQR Therapeutics N.V.$1.18-16.31%$166.5M
ELDNEledon Pharmaceuticals Inc.$1.97-6.86%$166.4M
IFRXInflaRx N.V.$1.18+0.85%$173.9M
KRROKorro Bio Inc.$12.71-6.61%$174.5M
WHWKWhitehawk Therapeutics Inc.$3.01-1.63%$177.6M
SLGLSol-Gel Technologies Ltd.$54.96-0.29%$179.9M

The full dossier has every filing, three years of financials, private raises and the people who signed them.

Open the full dossier